Paradoxical immune reconstitution inflammatory syndrome associated with rituximab-containing regimen in a patient with lymphoma

J Clin Oncol. 2013 Apr 10;31(11):e178-80. doi: 10.1200/JCO.2012.43.6188. Epub 2013 Feb 25.

Authors

Jonathan Canaani¹, Sharon Amit, Jonathan Ben-Ezra, Mehrzad Cohen Pour, Nadav Sarid, Hedva Lerman, Chava Perry, Aaron Polliack, Elizabeth Naparstek, Yair Herishanu

Affiliation

¹ Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

PMID: 23439758
DOI: 10.1200/JCO.2012.43.6188

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Murine-Derived / adverse effects
Antibodies, Monoclonal, Murine-Derived / immunology*
Antineoplastic Agents / adverse effects
Antineoplastic Agents / immunology
Antitubercular Agents / adverse effects
Antitubercular Agents / immunology
Diagnosis, Differential
Humans
Immune Reconstitution Inflammatory Syndrome / chemically induced
Immune Reconstitution Inflammatory Syndrome / diagnosis
Immune Reconstitution Inflammatory Syndrome / immunology*
Lymphoma / drug therapy
Lymphoma / immunology*
Male
Middle Aged
Mycobacterium tuberculosis / drug effects
Mycobacterium tuberculosis / immunology
Mycobacterium tuberculosis / isolation & purification
Rituximab
Tuberculosis, Pulmonary / drug therapy
Tuberculosis, Pulmonary / immunology
Tuberculosis, Pulmonary / microbiology

Substances

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Antitubercular Agents
Rituximab